Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.51 |
| ▸ | CDC25A | P30304 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | RARB | P10826 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5125380 | 0.99 | PARK7 (0.52) | PARK7CDC25ACES1RARBALDH1A1 | |
| SCHEMBL5117208 | 0.95 | PARK7 (0.54) | PARK7CDC25ACES1RARBALDH1A1 | |
| SCHEMBL5113902 | 0.94 | PARK7 (0.55) | PARK7CDC25ACES1RARBALDH1A1 | |
| SCHEMBL5124275 | 0.93 | PARK7 (0.54) | PARK7RARBALDH1A1MEN1RARA | |
| SCHEMBL5114060 | 0.91 | PARK7 (0.56) | PARK7CDC25ACES1RARBALDH1A1 | |
| SCHEMBL5117734 | 0.89 | CES1 (0.43) | PARK7CDC25ACES1ALDH1A1MEN1 | |
| SCHEMBL5110531 | 0.88 | ALDH1A1 (0.42) | PARK7CDC25ACES1ALDH1A1MEN1 | |
| SCHEMBL5111486 | 0.85 | PARK7 (0.44) | PARK7CDC25ACES1ALDH1A1MEN1 | |
| SCHEMBL5126140 | 0.84 | RARB (0.38) | PARK7CDC25ARARBALDH1A1MEN1 | |
| SCHEMBL14287353 | 0.84 | RARB (0.38) | PARK7CDC25ARARBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| EP-1828124-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063863-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | PARK7 2430/4885CDC25A 2380/4885CES1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.